Mohammad Ghani, MD
Interventional Cardiology · Oklahoma City, OKNPI 1134102916
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Edwards Lifesciences at 56.2% of the total.
Across 178 payments — averaging $211.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$21K
- Medtronic$10K
- Abbott$2K
- Ancora Heart, Inc.$2K
- Boston Scientific$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$221
- plus $946 from 15 others
Across 265 payments — averaging $6663.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$1.5M
- Medtronic$150K
- Procyrion, Inc.$76K
- Abbott$30K
- Artivion, Inc.$8K
- Philips North America LLC$2K
- plus $1K from 1 others
What the payments were for
- Consulting fees$12,60033%
- Travel & lodging$17,35546%
- Food & beverage$7,69920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 63 | $21,167 |
| Medtronic(2 entities) | 23 | $10,238 |
| Abbott | 18 | $1,829 |
| Ancora Heart, Inc. | 5 | $1,789 |
| Boston Scientific | 12 | $1,464 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $221 |
| Johnson & Johnson | 9 | $189 |
| Novartis | 8 | $152 |
| E.r. Squibb & Sons, L.L.C. | 7 | $126 |
| Heartflow, Inc. | 1 | $100 |
| AstraZeneca | 4 | $58 |
| Abiomed | 2 | $56 |
| Pfizer | 3 | $49 |
| Amgen | 2 | $41 |
| Vifor Pharma, Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Genentech USA, Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Gilead | 1 | $13 |
| Surmodics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$17,811
- COREVALVE EVOLUT R$9,716
- Watchman$1,200
- TRICLIP$1,186
- AccuCinch$836
- NAVITOR$150
- CoreValve Evolut$143
- CHOICE$123
- FFRct$100
How this compares
$37,654 in reported general payments places this provider in the 85th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 880 | $972,743 |
| EntrestoSacubitril/Valsartan | 284 | $350,419 |
| XareltoRivaroxaban | 136 | $160,943 |
| Repatha SureclickEvolocumab | 116 | $97,527 |
| BrilintaTicagrelor | 110 | $89,406 |
| JardianceEmpagliflozin | 48 | $50,709 |
| Ranolazine ErRanolazine | 317 | $32,645 |
| ClopidogrelClopidogrel Bisulfate | 1,161 | $22,444 |
| MultaqDronedarone Hcl | 12 | $20,871 |
| Atorvastatin Calcium | 1,046 | $14,732 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 967 | $12,995 |
| Metoprolol Succinate | 872 | $12,851 |
| Praluent PenAlirocumab | 18 | $12,529 |
| FarxigaDapagliflozin Propanediol | 17 | $10,740 |
| Clonidine | 63 | $10,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $49 | $972,743880 claims |
| NovartisEntresto | $152 | $350,419284 claims |
| Johnson & JohnsonXarelto | $189 | $160,943136 claims |
| AstraZenecaBrilinta, Farxiga | $58 | $100,146127 claims |
| Boehringer IngelheimJardiance | $39 | $50,70948 claims |
| Sanofi-aventis U.S. LLCMultaq | $32 | $20,87112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- George ChrysantOklahoma City$524K
- Jeffrey SparlingOklahoma City$231K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Marcus SmithOklahoma City$67K
- Parker TruongOklahoma City$44K
- Timothy DalyOklahoma City$31K
- Branislav SchifferdeckerOklahoma City$26K
- Mohit PahujaOklahoma City$21K
- Syed AliOklahoma City$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.